Quarterly report pursuant to Section 13 or 15(d)

Business combinations (Details)

v3.24.3
Business combinations (Details) - USD ($)
Jun. 01, 2023
May 31, 2023
Sep. 30, 2024
Dec. 31, 2023
Assets acquired        
Operating lease right-of-use assets     $ 20,494,000 $ 20,762,000
Liabilities assumed        
Operating lease liabilities, current     (4,175,000) (5,384,000)
Operating lease liabilities, non-current     $ (20,455,000) $ (19,851,000)
TCR2 Therapeutics        
Business Acquisition [Line Items]        
Percentage held following the transaction 25.00%      
Adaptimmune        
Business Acquisition [Line Items]        
Percentage held following the transaction 75.00%      
TCR2 Therapeutics        
Business Acquisition [Line Items]        
Shares issued 357,429,306 357,429,306    
Percentage of ownership 100.00%      
Market price   $ 1.02    
Ordinary share price per share   $ 0.17    
Intangible assets relation to lease contracts acquired $ 0      
Consideration transferred:        
Fair value of ordinary shares issued 60,763,000 $ 60,763,000    
Fair value of replacement options and RSU-style options granted attributable to pre-combination service 963,000      
Purchase consideration 61,726,000      
Assets acquired        
Cash and cash equivalents 43,610,000      
Restricted cash 1,654,000      
Marketable securities - available-for-sale debt securities 39,532,000      
Other current assets and prepaid expenses 6,029,000      
Property, plant and equipment 2,712,000      
Operating lease right-of-use assets 5,145,000      
Intangible assets 58,000      
Total assets acquired 98,740,000      
Liabilities assumed        
Accounts payable (6,210,000)      
Accrued expenses and other current liabilities (4,537,000)      
Operating lease liabilities, current (1,974,000)      
Operating lease liabilities, non-current (2,244,000)      
Total liabilities assumed (14,965,000)      
Net assets acquired and liabilities assumed $ 83,775,000